Partial Least Square and Hierarchical Clustering in ADMET Modeling: Prediction of Blood - Brain Barrier Permeation of alpha-Adrenergic and Imidazoline Receptor Ligands by Nikolić, Katarina et al.




Partial Least Square and Hierarchical Clustering in ADMET Modeling: 
Prediction of Blood – Brain Barrier Permeation of α-Adrenergic and 
Imidazoline Receptor Ligands 
 
Katarina Nikolic1, Slavica Filipic1, Adam Smoliński2, Roman Kaliszan3, and Danica Agbaba1 
 
1 Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe Belgrade, Serbia. 
2 Central Mining Institute, Department of Energy Saving and Air Protection, Katowice, Poland. 3 Department of 
Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gdańsk, Poland. 
 
Received, June 26, 2013; Revised, September 18, 2013; Accepted, October 13, 2013; Published, October 30, 2013 
 
ABSTRACT - PURPOSE. Rate of brain penetration (logPS), brain/plasma equilibration rate (logPS-brain), 
and extent of blood-brain barrier permeation (logBB) of 29 α-adrenergic and imidazoline-receptors ligands 
were examined in Quantitative-Structure-Property Relationship (QSPR) study. METHODS. Experimentally 
determined chromatographic retention data (logKw at pH 4.4, slope (S) at pH 4.4, logKw at pH 7.4, slope 
(S) at pH 7.4, logKw at pH 9.1, and slope (S) at pH 9.1) and capillary electrophoresis migration parameters 
(μeff at pH 4.4, μeff at pH 7.4, and μeff at pH 9.1), together with calculated molecular descriptors, were used as 
independent variables in the QSPR study by use of partial least square (PLS) methodology. RESULTS. 
Predictive potential of the formed QSPR models, QSPR(logPS), QSPR(logPS-brain), QSPR(logBB), was 
confirmed by cross- and external validation. Hydrophilicity (Hy) and H-indices (H7m) were selected as 
significant parameters negatively correlated with both logPS and logPS-brain, while topological polar 
surface area (TPSA(NO)) was chosen as molecular descriptor negatively correlated with both logPS and 
logBB. The principal component analysis (PCA) and hierarchical clustering analysis (HCA) were applied to 
cluster examined drugs based on their chromatographic, electrophoretic and molecular properties. 
Significant positive correlations were obtained between the slope (S) at pH 7.4 and logBB in A/B cluster and 
between the logKw at pH 9.1 and logPS in C/D cluster. CONCLUSIONS. Results of the QSPR, clustering 
and correlation studies could be used as novel tool for evaluation of blood-brain barrier permeation of 
related α-adrenergic/imidazoline receptor ligands. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 





Earlier findings that clonidine and its analogues 
produce central hypotensive effect by interaction 
with both the α2-adrenoreceptors (α2-AR) and 
imidazoline receptors (IRs) (1, 2) influenced on 
development of novel guanidines/imidazolines as 
multipotent centrally acting antihypertensives (3-
5). Until today three subtypes of imidazoline 
receptors, I1-IR, I2-IR, and I3-IR, were 
experimentally characterized (6, 7). The I1-IRs 
were defined as one of the binding sites involved 
in the control of blood pressure (8). The I1-IRs 
have high affinity for clonidine, moxonidine, and 
rilmenidine, while the I2-IRs has high affinity for 
idazoxan and its analogues (9, 10). 
Selective I1-IR ligands as rilmenidine and 
moxonidine induce fall in plasma catecholamines, 
rennin, and antidiuretic hormone (11, 12), which 
result in increase of renal blood flow, natriuresis, 
potassium excretion, and diuresis (13). 
For the active sites of I2-IRs were shown to 
reside on monoamine oxidase-B (MAO-B) (10), 
well known drug target for several neurological 
diseases. Therefore the I2-IRs ligands are 
examined as novel therapeutic drugs in treatment 
of various neurological diseases (14).  Research 
on agmatine, an endogenous ligand for all 
imidazoline receptor(s), has confirmed its 
implication in mediation of analgesia, stress 
responses, convulsions, and neuroprotection (15). 
Since the IRs are involved in many 
neurophysiologic and pathologic functions the 
potential for new IRs ligands development is very 
intriguing (14, 15). 
Thus, the main goal of the study was to 
examine brain penetration of the drugs interacting 
with IRs/α-ARs and to develop Quantitative 
Structure-Property Relationship (QSPR) models 
capable to predict and describe rate and extent of 
the brain penetration for the related IRs/α-ARs 
ligands. 
________________________________________ 
Corresponding Author: Katarina Nikolic, Institute of 
Pharmaceutical Chemistry, Faculty of Pharmacy, University 
of Belgrade, Belgrade, Serbia; E-mail: 
knikolic@pharmacy.bg.ac.rs 




Initially, we have selected ligands of α-
adrenergic and imidazoline-receptors for the 
study. 
Because the I-IR ligands exert additional CNS 
and diuretic effects, we have decided to include 
few structurally related CNS drugs (clozapine, 
maprotiline, mianserin, and olanzapine) and 
diuretics (amiloride, clopamide, indapamide, and 
triamterene) in the QSPR study. 
Rate of brain penetration (logPS), 
brain/plasma equilibration rate (logPS-brain), and 
extent of blood-brain barrier permeation (logBB) 
of the 29 α-adrenergic/imidazoline receptors 
ligands and related compounds were used as 
dependent (Y) variables in the QSPR study. 
The QSPR (logPS, logPS-brain, logBB) study 
of the 29 drugs was performed by use of principal 
component analysis (PCA) and partial least 
square (PLS) methodologies. 
Chromatographic retention parameters 
(logKw at pH 4.4, slope (S) at pH 4.4, logKw at 
pH 7.4, slope (S) at pH 7.4, logKw at pH 9.1, and 
slope (S) at pH 9.1), capillary electrophoresis 
migration parameters (μeff at pH 4.4, μeff at pH 
7.4, and μeff at pH 9.1) and computed molecular 
parameters of the drugs were used as independent 
variables (X) for the QSPR modeling. The PLS 
methodology was applied to select molecular 
parameters of the drugs with the strongest impact 
on their brain penetration and to create QSPR 
(logPS, logPS-brain, logBB) models able to 
predict blood-brain barrier permeation properties 
of the related α-adrenergic/imidazoline receptors 
ligands. 
Since the examined drugs are structural very 
diverse principal component analysis (PCA) and 
hierarchical clustering analysis (HCA) were 
applied to cluster examined drugs based on their 
chromatographic, electrophoretic and molecular 
properties. The PCA/HCA clusters of the drugs 
were further examined by the correlation study 
between chromatographic/electrophoretic 
parameters, as independent variables, and blood-
brain permeation parameters, as dependant 
variables. 
The performed QSPR, clustering and 
correlation studies are first reported theoretical 
investigation of brain penetration process of the α-
adrenergic/imidazoline receptor ligands.  
MATHERIALS AND METHODS 
Chemicals and reagents 
All reagents used were of analytical grade purity. 
Methanol-HPLC gradient grade, glacial acetic 
acid (J.T. Baker Deventer, Netherlands), 
ammonium acetate, sodium hydroxide, sodium 
dihydrogen phosphate, disodium hydrogen 
phosphate, (Merck, Darmstadt, Germany), boric 
acid (Sigma-Aldrich, St. Louis, MO, USA), 
ammonium hydroxide (Carlo Erba, Milan, Italy) 
and water-HPLC grade were used to prepare 
mobile phases and background electrolytes. 
The following standards were used: clonidine 
hydrochloride, moxonidine hydrochloride, 
guanfacine hydrochloride, brimonidine 
hydrochloride, efaroxan hydrochloride, idazoxan 
hydrochloride, rilmenidine hemifumarate, 
harmane, harmine hydrochloride, tizanidine 
hydrochloride, triamterene, clopamide, 
indapamide, naphazoline hydrochloride, 
xylometazoline hydrochloride, tetrahydrozoline 
hydrochloride, oxymetazoline hydrochloride, 
ephedrine hydrochloride, pseudoephedrine 
hydrochloride, maprotiline hydrochloride, 
tamsulosin hydrochloride, mianserin 
hydrochloride, carvedilol, clozapine and 
olanzapine (Sigma-Aldrich, St. Louis, MO, USA); 
tramazoline hydrochloride and doxazosin mesilat 
(Zdravlje, Leskovac, Serbia); amiloride 
hydrochloride (Galenika, Belgrade, Serbia); 






Stock solutions of harmane, harmine, clopamide, 
indapamide, rilmenidine, mianserin, doxazosin, 
carvedilol, clozapine, olanzapine and triamterene 
were prepared in methanol and diluted with water 
to a final concentration of methanol 2 % for 
triamterene and 1 % for remaining substances. 
Brimonidine was dissolved in 0.1% formic acid 
and the other 17 compounds were dissolved in 
water. Acetone 2% was used as EOF marker. 
Samples were prepared in different 
concentrations, from 5.8 to 60 μg mL-1, depending 
on their UV response and solubility. 
 
HPLC analysis 
Working solutions were prepared by dissolving 
the substances into the methanol in order to obtain 
the concentration of 0.7 mg mL-1 for rilmenidine 
and 0.1 mg mL-1 for the remaining compounds. 
 
CE equipment 
All experiments were carried out on 
SpectraPhoresis 500-capillary electrophoretic 
system (Spectra Physics Analytical, USA) 
equipped with UV detector. Data were recorded 
and analyzed with ChromQuest software version 
4.0 (Thermo Finnigan, USA). 





Separations were performed using an uncoated 
fused capillary (31,5 cm_50 mm id, effective 
length 24 cm, Polymicro Technologies, USA) at 
25 ºC, 11 kV, and 200 nm. The new capillary was 
gradually flushed with 0.1 M NaOH (15 min), 
water (10 min) and running buffer (10 min).  
Finally, a 10 min application of the high voltage 
through the capillary filled with background 
electrolyte were applied in order to equilibrate the 
inner surface, stabilize electroosmotic flow and to 
maintain proper reproducibility of run-to-run 
injections. Background solutions of constant ionic 
strength (I=25 mmol/L) were prepared at three 
different pH values (4.4; 7.4 and 9.1). The 
samples were injected hydrodynamically three 
times at each pH (4.4; 7.4 and 9.1). Between runs 
the capillary was rinsed with the background 
electrolyte for 1 min. 
The effective electrophoretic mobility, μeff, of 
the analyte at three different pH values 4.4; 7.4 
and 9.1 (μeff pH 4.4, μeff  pH 7.4 and μeff  pH 9.1 




A chromatographic system Agilent Technologies 
1200 (Wilmington, DE, USA) equipped with on-
line degasser, binary pump, column oven and 
photo diode array detector was used for HPLC 
analysis. Sample injection was performed through 
Rheodyne injector valve with a 20 μL sample 
loop. Data were recorded and analyzed with 
Agilent's ChemStation software. 
 
HPLC conditions 
All chromatographic measurements were 
performed on XTerra® RP18 column, 4.6 x 100 
mm, particle size 3.5 µm (Waters Corporation, 
Milford, MA, USA). The flow rate was 0.8 ml 
min-1 with UV detection in the range 200-280 nm. 
The temperature was set at 25°C. The retention 
parameters were obtained at the isocratic elution 
mode using at least six mobile phases 
methanol/buffer with concentration of methanol 
varying from 75-2%, depending on compounds 
retention properties. Buffers solutions of constant 
ionic strength (I=25 mmol/L) were prepared at 
three different pH values: 4.4, 7.4 and 9.1. Dead 
volume was measured with KNO3 as a non-
retained marker. The values corresponding to 
100% of buffered eluent, log Kw and slope (S), 
were obtained by extrapolation, following the 
Snyder-Soczewinski equation (16, 17). The logKw 
and slope (S)of the analyte at three different 
experimental conditions, methanol/buffer pH 4.4,  
methanol/buffer pH 7.4 and methanol/buffer pH 
9.1 (logKw pH 4.4, slope (S)pH 4.4, logKw pH 7.4, slope 
(S)pH 7.4, logKw pH 9.1, and slope (S)pH 9.1 
respectively) were calculated for all examined 
compounds and used for QSPR study. 
 
Computational Method 
Among analyzed compounds (Figure 1), cyclic 
amidines and guanidines structures such as 
moxonidine, clonidine, tizanidine, rilmenidine, 
brimonidine and tramazoline can exist in two 
major tautomeric forms (amino and imino). 
The dominant amino/imino tautomers were 
selected by use of the B3LYP/6–31G(d, p) level 
of the Density Functional Theory (DFT) (18, 19) 
incorporated in  the Gaussian 98 program (20). 
The selected basis set was proved to be good 
choice for examination of the related amidines 
and guanidines (21). Based on the obtained Self 
Consistent Field Energy (SCF energy), 
rilmenidine amine was selected as predominant 
tautomeric form while moxonidine, clonidine, 
tizanidine, brimonidine and tramazoline exist as 
more stable imino tautomers. 
Calculation of pKa and selection of dominant 
molecules/cations species at pH 4.4, 7.4, and 9.1, 
have been performed for 29 α-adrenergic and 
imidazoline-receptors ligands using the Marvin 
5.5.1.0 ChemAxon program (22). The Marvin 
program defined nitrogens of the analyzed 
structures with the highest potential to attract 
proton at analytical pH. 
The geometries of the examined ligands 
(selected tautomers and molecules/cations species 
at three different pH values) were completely 
optimized at B3LYP/3–21(d,p) levels of the 




The molecular descriptors, as numerical 
parameters representing the chemical structures, 
were calculated for the optimized molecular 
models. The Density-Functional-
Theory/B3LYP/3-21G(d,p) basis set (18-20), the 
Marvin 5.5.1.0 ChemAxon (22), Chem3D Ultra 
7.0.0 programs (23), and Dragon programs (24) 
were applied  for computation  of  constitutional, 
physico-chemical, thermodynamic and electronic 
parameters of the optimized molecular models. 
Also, quantum chemically-based reactivity 
descriptors, such as chemical potential (μ), 
electronegativity (χ), hardness (η), global softness 
(GS), and electrophilicity index (ω), were added 
to the set of calculated molecular descriptors of 
the analyzed data set (25, 26).   





Pharmacokinetic parameters of the examined 29 
α-adrenergic and imidazoline-receptors ligands 
(logPS, logPS-brain, and logBB), calculated by 
use of ACD/i-Lab program (27), were used as 
dependant (Y) variable in the QSPR study. The 
HPLC retention parameters (logKw and Slope at 
pH 4.4, 7.4, and 9.1), CE migration parameters 
(μeff at pH 4.4, 7.4, and 9.1), and calculated 
molecular descriptors (18-20, 22-24) of the 
examined ligands were used as independent (X) 
variables in the QSPR study by use of the partial 
least square (PLS) Regression (28). 
The Soft Independent Modeling of Class 
Analogy SIMCA P+ 12.0 program (29) was used 
for the PLS analysis and QSPR modeling. 
Based on the Principal Component Analysis 
(PCA) plots (t1 vs. t2 and t1 vs. u1) the data set of 
29 compounds is divided on Training Set (22 
compounds for QSPR models building) and 
Verification set (7 compounds for QSPR models 
validation). Based on the PCA plots were not 
defined any outlier in the QSPR models. 
Partial least square (PLS) regression, recently 
developed generalization of multiple linear 
regressions (MLR) (28, 29), has been used for 
calculation of VIP parameter and QSAR models 
building. In multilinear modeling, a summary of 
the importance of each variable (xk), for both Y 
and X matrices, is presented as VIPk parameter. 
The x-variables with VIP value larger than 1 are 
the most relevant for explaining the regression 
model, the x-variables with 1.0>VIP>0.5 are 
moderately influential, while x-variables with VIP 
value smaller than 0.5 are not relevant for the 





Figure 1. Structural formulas of the examined α-adrenergic/imidazoline receptor ligands and related compounds. 







Figure 1. Structural formulas of the examined α-adrenergic/imidazoline receptor ligands and related compounds.  
 
 
Descriptors with lowest VIP-value are 
successively removed from the PLS model and 
new PLS model is created. For each new model 
are calculated regression factors R2, Q2, F ratio, P-
value, root mean square error of estimation 
(RMSEE), and compared with the previous 
model. The procedure is repeated until the best 
model is created. 




Quality of the obtained QSPR models was 
examined by use of the R2, Q2 and RMSEE, CV-
ANOVA analysis of variance testing of cross-
validated predictive residuals (F- and P-value), 
and external validation (root mean square error of 
prediction (RMSEP),  R2pred,  R2Obs vs. Pred) (28, 30, 
31). 
Predictive power of the model is determined 
by Q2, which is Leave-One-Out Cross-Validated 
(LOO-CV)/or Leave-n-Out Cross-Validated 
(LnO-CV) version of R2. A model is fitted to the 
data leaving one/or more compounds out, 
computing VIP, selecting the best variables, and 
than predicting Y for the left–out compounds. 
This procedure is repeated until all compounds 
have been left out, which result in many parallel 
models. The difference between observed and the 
predicted Y values are calculated (e(i)) for each 
model. In this setting were defined PRESS 
(Predicted Sum of Squares), RMSE (RMSEE and 
RMSEP) and Q2 as: 
 
 ni iePRESS 1 2 )(      (1) 
Difference between observed and the predicted Y 
values - (e(i)) 
 
n
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QSPR models with Q2 0.5 can be considered 
to have good predictive capability (28, 29) 
 
Quality of the QSPR models prediction was 
assessed on test set by use of the RMSEP, R2Obs vs. 
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QSPR models with R2pred 0.5 can be 
considered to have good predictive capability 
(31). 
The response permutation test (Y scrambling) 
examined the statistical significance of the R2 and 
Q2 and overfitting due to the chance correlation 
(28, 30). In this test the Y-matrix is randomly re-
ordered (100 times in this project) while the X-
matrix is kept intact. Model is fitted to the new Y-
data and the new R2(Y), Q2 and VIP parameters 
are calculated. All model selection steps are 
repeated on the scrambled Y-response data. Lines 
are fitted through the R2-values and through the 
Q2-values, yielding two separate intercepts. For a 
valid model, the R2 - intercept should not exceed 
the 0.4 while the Q2-intercept < 0.05 (28). 
The F-test, based on the ratio MS 
Regression/MS Residual, formally assesses the 
significance of the model. The P-value indicates 
the probability level where a model with this F-
value may be the result of just chance. The 
common practice is to interpret a P-value lower 
than 0.05 as pointing to a significant model (28).  
 
Principal component analysis and hierarchical 
clustering analysis 
The Principal component analysis (PCA) (32) is 
one of the most common methods used in a two-
way data analysis. In PCA a two-way matrix, X 
(m × n), is decomposed into two matrices S 
(m × fn) and D (n × fn): 
 
X (m × n) = S (m × fn) · D’ (n × fn) + E (m × n) 
 
where m and n denote, respectively, the number 
of objects and the number of variables, S 
represents the scores matrix, D represents the 
loading matrix, E is the residuals matrix, and fn 
denotes the number of significant factors. Scores 
and loadings matrices are orthogonal, i.e. 
S′S = D′D = I. The columns of matrix S are called 
the Principal Components (PC), or eigenvectors. 
Each PC is constructed as a linear combination of 
original variables with weights maximizing 
description of the data variance (i.e. S = XD). The 
sum of the squared elements of each eigenvector 
(PC) is called an eigenvalue. The first PC 
describes the largest amount of the data variance, 
so that the associated eigenvalue also has the 
highest value. The sum of the eigenvalues defines 
the total variance of the data. Scores vectors (i.e. 
the columns of matrix S) and loading vectors (i.e. 
the columns of matrix D) are used to visualize 
relationships between the objects and the 
parameters in a matrix X. 
Hierarchical clustering analysis (HCA) can be 
applied to multidimensional data sets, in order to 
study similarities (or dissimilarities) of objects in 
the variables space, or similarities of variables in 
the objects space (33). Final results of hierarchical 
clustering are presented in a form of a 
dendrogram. The indices of clustered objects (or 
variables) are displayed on axis x of the 
dendrogram, whereas axis y represents the 
corresponding linkage distances (or an adequate 
measure of similarity) between the two objects or 
clusters, which are merged. 






Quantitative Structure-Property Relationship 
(QSPR) study 
The pharmacokinetic properties (logPS, logPS-
brain, and logBB) of the 29 ligands (Figure 1), 
calculated by use of ACD/i-Lab program (27), 
were used as dependent (Y) variables in the 
QSPR study. Values of the logPS, logPS-brain, 
and logBB parameters are reflecting rate and 
extent of blood-brain permeation process, where 
higher logPS, logPS-brain, and logBB values 
indicate on higher rate and extent of brain 
penetration of a ligand. 
The HPLC retention parameters (logKwpH 4.4, 
SpH 4.4, logKwpH 7.4, SpH 7.4, logKwpH 9.1, and SpH 9.1) 
and CE migration parameters (μeffpH 4.4, μeffpH 7.4, 
and μeffpH 9.1), and calculated molecular parameters 
of the optimized molecular models were used as 
independent (X) variables. The Density-
Functional-Theory/B3LYP/3-21G(d,p) basis set 
(18-20), Marvin 5.5.1.0 ChemAxon (22), 
Chem3D Ultra 7.0.0 (23), and Dragon (24) 
programs were applied  for computation of 
constitutional, physico-chemical, thermodynamic, 
electronic, and quantum chemically-based 
reactivity descriptors (25, 26) of the optimized 
molecular models. 
Based on the obtained Score Plots (t1 vs. t2 
and t1 vs. u1) the data set of 29 α-adrenergic and 
imidazoline-receptors ligands is divided on 
Training set (22 compounds for QSPR models 
building) and test set (7 compounds for QSPR 
models validation) (28, 30, 31).  
The rate of brain penetration (logPS) was 
spanned 3.9 log units (-5.3 – (-1.4)), the 
brain/plasma equilibration rate (logPS-brain) 
interval was 2.9 log units (-5.3 – (-2.4)), while the 
extent of blood-brain barrier (BBB) permeation 
(logBB) was spanned 2.97 log units (-2.00 – 0.97) 
in the Training sets. The domain of applicability 
for the QSPR models is defined by the rate of 
brain penetration (logPS: -5.3 – (-1.4)), the 
brain/plasma equilibration rate (logPS-brain: -5.3 
– (-2.4)), and the extent of blood-brain barrier 
(BBB) permeation (logBB: -2.00 – 0.97) of the 
Training sets. Relatively wide Y intervals of the 
Training sets provide extensive applicability 
domain for the formed QSPR models. 
Quality of the logBB prediction (27) was 
examined on three drugs from the Data set 
(clonidine (34), mianserine (35) and olanzapine 
(36)) and seven related drugs (imipramine (34), 
mirtazapine (35), phenytoin (37), tacrine (38), 
acebutolol (39), alprenolol (39), and pindolol 
(39). Relatively high correlation coefficient (r: 
0.776) between experimental (34-39) and 
predicted (27) logBB values (Figure 2) indicated 
on good predictive potential of the ACD/i-Lab 
program for calculation of logBB parameter for 
the examined α-adrenergic and imidazoline-
receptors ligands (Table 1). 
The PLS methodology was applied for 
selection of the most relevant molecular 
descriptors and QSPR models building. 
Descriptors with lowest Variable Importance 
in the Projection (VIP) value are successively 
removed from the PLS model, each time new PLS 
model is created, and the obtained R2, Q2, F ratio, 
P-value, RMSEE of new model were compared 
with the previous one. The procedure is repeated 
until the best model is created. 
The applied PLS methodology has selected 
sets of significant descriptors during development 
of each QSPR model. Overfitting of the QSPR 
models is avoided by continual monitoring of the 
RMSE for training and test set during the QSPR 
modeling. The QSPR models were selected when 
RMSEP of test set begins to increase while 
RMSEE of training set continues do decrease. 
Furthermore, the QSPR models with different 
number of selected significant descriptors were 
compared and optimal one is chosen by 
comparing statistical parameters of the training 
set, such as R2, Q2 (Leave-One-Out Cross 
Validation (LOO-CV), Leave-n-Out Cross 
Validation (LnO-CV)), RMSEE, F ratio, and P-
value, and also statistical parameters of the test 
set, such as R2Obs vs. Pred, R2pred, and RMSEP. Apart 
from the Leave-One-Out Cross Validation, in the 
QSPR study was performed Leave-2-Out Cross-
Validation (L2O-CV) and Leave-3-Out Cross-
Validation (L3O-CV). 
Optimal QSPR models for each 
pharmacokinetic parameter (logPS, logPS-brain, 
and logBB) were selected by use of statistical 
parameters of the training and test set (Tables 2-
4).   
In order to investigate the statistical 
significance of the R2 and Q2 and to test the model 
for overfitting due to the chance correlation the 
response permutation test (Y scrambling) is 
applied for all QSPR models. The R2 – intercepts 
were less than 0.1 (upper limit is 0.4), while the 
Q2-intercepts were less than -0.1 (upper limit is 
0.05) for all developed QSPR models. Thus the 
response permutation test results have proved 
good quality of the formed QSPR models.  
 





Figure 2.  Observed vs. predicted logBB for adrenergic/imidazoline receptor ligands and related compounds. 
 
 
Table 1. Experimental and predicted logBB for adrenergic/imidazoline receptor ligands and related compounds. 
Name Experimental LogBB Predicted logBB, ACD/i-Lab (27) 
Clonidine 0.11 (34) -0.46 
Mianserine 0.99 (35) 0.47 
Olanzapine 0.33 (36) 0.18 
Imipramine 1.06 (34) 0.81 
Mirtazapine 0.53 (35) 0.85 
Phenytoin -0.04 (37) -0.11 
Tacrine -0.12 (38) -0.21 
Acebutolol -0.15 (39) 0.27 
Alprenolol -0.23 (39) -0.21 
Pindolol -0.14 (39) -0.21 




The optimal QSPR (logPS) model with one 
significant components (A=1), relating five 
variables (Mi, H7m, R3s+, Hy, and TPSA(NO)), 
R2: 0.794, LOO-CV/Q2: 0.748, L2O-CV/Q2: 
0.740, L3O-CV/Q2: 0.744, F-ratio: 28.149, P-
value: 2.08E-06, and RMSEE: 0.409 (Table 2), 
was selected.  
Significant descriptors of the QSPR (logPS) 
model are: Mi - mean first ionization potential 
(scaled on Carbon atom)/Constitutional indices-
Basic descriptors; H7m - H autocorrelation of lag 
7 (weighted by mass GETAWAY descriptors)/H-
indices; R3s+ - R maximal autocorrelation of lag 
3 (weighted by I-state GETAWAY 
descriptors)/R-indices, Hy - hydrophilic 
factor/Molecular properties-Basic descriptors, 
and TPSA(NO) - topological polar surface area 
using N,O polar contributions/Molecular 








Table 2. Statistical parameters and predicted brain penetration obtained by QSPR (logPS) study. SD - Standard 
Deviation, SE – Standard Error: NSDSE / . 
Training Set Brain penetration 
Primary ID Name logPS (27) QSPR-predicted logPS 
1 Amiloride -5.3 -5.607 
2 Brimonidine -3.3 -2.805 
3 Carvedilol -2.0 -2.616 
5 Clopamide -2.3 -2.753 
6 Clozapine -3.3 -2.397 
7 Doxazosin -2.9 -2.849 
8 Efaroxan -2.1 -1.986 
9 Ephedrine -3.0 -2.512 
10 Guanfacine -2.3 -2.833 
11 Harmane -1.4 -1.773 
12 Harmine -1.4 -1.831 
13 Idazoxan -2.6 -2.139 
15 Maprotiline -1.4 -1.685 
17 Moxonidine -3.1 -3.011 
18 Naphazoline -1.6 -1.788 
19 Olanzapine -1.9 -2.043 
22 Pseudoephedrine -3.0 -2.475 
23 Rilmenidine -2.1 -2.174 
24 Tamsulosin -3.4 -3.214 
26 Tizanidine -3.2 -2.912 
28 Tramazoline -2.5 -2.203 
29 Xylometazoline -1.5 -1.992 
F-Ratio 28.149 R2 0.794 
P-value 2.08E-06 LOO - Q2 0.748 
 RMSEE 0.409 
PLS equation:  
Descriptor PLS coefficient SE (PLS coefficient) PLS - Intercept 
Mi -0.208015 0.114865 -2.73863 
H7m -0.196653 0.106972  
R3s+ -0.218820 0.067949  
Hy -0.203340 0.039503  
TPSA(NO) -0.186372 0.099012  
Test Set     
Primary ID Name logPS (27) QSPR-predicted logPS 
4 Clonidine -2.8 -2.658 
14 Indapamid -2.2 -2.601 
16 Mianserine -1.1 -1.553 
20 Oxymetazoline -2.0 -2.407 
21 Phenilephrine -3.6 -2.848 
25 Tetrahydrozoline -1.8 -1.925 
27 Triamterene -3.2 -3.211 
SD (predicted logPS)=0.758443 R2Obs vs. Pred 0.823 
   R2pred 0.747 
    RMSEP 0.402 
 
 
Since all PLS coefficients of the QSPR (logPS) 
model are negative numbers (Figure 3a, Table 2) 
was concluded that all significant descriptors (Mi, 
H7m, R3s+, Hy, and TPSA(NO)) are in negative 
correlation with rate of brain penetration - logPS. 
Actually, increase in hydrophilicity (Hy), 
topological polar surface area (TPSA(NO)), mean 
first ionization potential (Mi), H-indices (H7m), 
and R-indices (R3s+) of a ligand will lead to 
decrease of rate of brain penetration (logPS). 




Also, decrease in hydrophilicity (Hy), topological 
polar surface area (TPSA(NO)), mean first 
ionization potential (Mi), H-indices (H7m), and 
R-indices (R3s+) of a ligand will lead to increase 
of rate of brain penetration (logPS). 
Constitutional descriptors are descriptors 
reflecting the chemical composition of a 
compound without any information about its 
molecular geometry or atom connectivity. The 
mean first ionization potential (such as Mi) of a 
molecule is amount of energy required to remove 
an electron from the molecule in the gaseous 
state. 
Generally, the GETAWAY (GEometry, 
Topology, and Atom-Weights AssemblY) 
descriptors (40, 41) are chemical structure 
descriptors derived from the Molecular Influence 
Matrix. H-indices (such as H7m) are based on the 
spatial autocorrelation formulas, weighting the 
molecule atoms by physico-chemical properties w 
together with 3D information encoded by the 
elements of the molecular influence matrix H. R-
indices (such as R3s+) include some descriptors 
obtained by applying traditional matrix operators 
to the influence/distance matrix R and 
autocorrelations calculated by weighting the 
molecule atoms by physico-chemical properties w 
together with 3D information encoded by the 
elements of the influence/distance matrix. The H, 
R and maximal R+ indices are molecular 
descriptors based on spatial autocorrelation, 
encode information on structural fragments and, 
therefore, seem to be particularly suitable for 
describing differences in congeneric series of 
molecules. Also, GETAWAY descriptors are 
geometrical descriptors encoding information on 
the effective position of substituents and 
fragments in the molecular space and provide 
information about molecular size, shape, and 
specific atomic properties (40, 41).  
The hydrophilic factor (Hy) is a 
hydrophilicity descriptor defined by Todeschini et 
al (42).  
The topological polar surface area (TPSA) is 
based on a group contribution method, calculated 
according to the model proposed by Ertl (43). The 
TPSA(NO) is topological polar surface area 
derived only from polar fragments with nitrogen 
and oxygen. The TPSA(NO) of a molecule is 
determined by the summation of tabulated surface 
contributions of the polar atom types. The 
topological polar surface area descriptors were 
successfully used in validation studies based on 
sets of published absorption data, including 
intestinal absorption, Caco-2 monolayer 
penetration, and blood-brain barrier penetration 
(43). 
Predictive potential of the QSPR (logPS) 
model was tested by use of leave-one-out cross 
validation of the training set (LOO-CV/Q2: 0.748, 
L2O-CV/Q2: 0.740, L3O-CV/Q2: 0.744, RMSEE: 
0.409) and evaluation of the verification set 
(R2Observed vs. Predicted: 0.823, RMSEP: 0.402, and 
R2pred: 0.747) (Table 2). The obtained statistical 
parameters proved that the QSPR (logPS) model 
has acceptable accuracy for predicting rate of 
brain penetration (logPS) of the α-adrenergic and 
imidazoline receptor ligands.  
The QSPR (logPS-brain) model with three 
significant components (A=3), relating five 
variables (GATS1e, H7m, nHDon, T(N..N), and 
Hy), R2: 0.954, LOO-CV/Q2: 0.923, L2O-CV/Q2: 
0.918, L3O-CV/Q2: 0.926, F-ratio: 29.935, P-
value: 1.57E-07, and RMSEE: 0.122 (Table 3), 
was derived. 
Significant descriptors of the QSPR (logPS-
brain) model are: GATS1e - Geary 
autocorrelation of lag 1 weighted by Sanderson 
electronegativity/2D autocorrelations-Geary 
autocorrelations; H7m - H autocorrelation of lag 
7 (weighted by mass GETAWAY 
descriptors)/H-indices; nHDon - number of donor 
atoms for H-bonds (N and O)/Functional group 
counts-Basic descriptors, T(N..N) - sum of 
topological distances between N..N/2D Atom 
Pairs-Weighted topological atom pairs, and Hy - 
hydrophilic factor/Molecular properties-Basic 
descriptors.  
Negative sign of all PLS coefficients in the 
QSPR (logPS-brain) model (Figure 3b, Table 3) 
indicated that all significant descriptors (GATS1e, 
H7m, nHDon, T(N..N), and Hy) are in negative 
correlation with the brain/plasma equilibration 
rate – logPS-brain. Actually, increase in Geary 
autocorrelations (GATS1e) parameter, H-indices 
(H7m), number of donor atoms for H-bonds 
(nHDon), sum of topological distances between 
N..N (T(N..N)), and stronger hydrophilicity (Hy) 
of a ligand will lead to decrease of logPS-brain 
Also, decrease in Geary autocorrelations 
(GATS1e) parameter, H-indices (H7m), number 
of donor atoms for H-bonds (nHDon), sum of 
topological distances between N..N (T(N..N)), 
and stronger hydrophilicity (Hy)of a ligand will 









Table 3. Statistical parameters and predicted brain/plasma equilibration rates obtained by QSPR (logPS-brain) 
study. SD - Standard Deviation, SE – Standard Error: NSDSE / . 
Training Set Brain/plasma equilibration rate 
Primary ID Name logPS-brain (27) QSPR-predicted logPS-brain 
1 Amiloride -5.3 -5.320 
2 Brimonidine -3.5 -3.429 
3 Carvedilol -3.3 -3.498 
5 Clopamide -2.7 -2.605 
6 Clozapine -3.4 -3.393 
7 Doxazosin -3.2 -3.219 
8 Efaroxan -2.8 -2.673 
9 Ephedrine -3.2 -3.166 
10 Guanfacine -2.9 -2.895 
11 Harmane -2.4 -2.721 
12 Harmine -2.5 -2.666 
13 Idazoxan -2.9 -2.682 
15 Maprotiline -3.4 -3.249 
17 Moxonidine -3.2 -3.228 
18 Naphazoline -3.0 -3.028 
19 Olanzapine -3.2 -3.242 
22 Pseudoephedrine -3.2 -3.160 
23 Rilmenidine -2.6 -2.671 
24 Tamsulosin -3.8 -3.617 
26 Tizanidine -3.5 -3.592 
28 Tramazoline -3.2 -3.210 
29 Xylometazoline -3.2 -3.136 
F-Ratio 29.935 R2 0.954 
P-value 1.57E-07 Q2 0.923 
  RMSEE 0.122 
PLS equation:  
Descriptor PLS coefficient SE (PLS coefficient) PLS - Intercept 
GATS1e -0.332009 0.171041 -5.48028 
H7m -0.497359 0.343375  
nHDon -0.183323 0.132481  
T(N...N) -0.183561 0.250992  
Hy -0.133735 0.156820  
Test Set     
Primary ID Name logPS-brain (27) QSPR-predicted logPS-brain 
4 Clonidine -3.0 -3.018 
14 Indapamid -2.7 -2.630 
16 Mianserine -2.5 -2.717 
20 Oxymetazoline -3.3 -3.101 
21 Phenilephrine -3.7 -3.247 
25 Tetrahydrozoline -2.9 -3.049 
27 Triamterene -3.5 -3.966 
 SD(predict logPS-brain)=0.535428 R2Obs vs. Pred 0.586 
   R2pred 0.560 
    RMSEP 0.277 
 
 
Geary autocorrelations (GATS1e) lag 1 weighted 
by Sanderson electronegativity is calculated by 
applying Geary coefficient to the H-filled 
molecular graph. Geary coefficient is a distance-
type function varying from zero to infinite. Strong 
spatial autocorrelation produces small values of 
this index. Positive autocorrelation translates in 
values between 0 and 1 whereas negative 
autocorrelation produces values larger than 1. 
H-indices (such as H7m) are based on the 
spatial autocorrelation formulas, weighting the 
molecule atoms by physico-chemical properties w 




together with 3D information encoded by the 
elements of the molecular influence matrix H (40, 
41).  
The number of donor atoms for H-bonds 
(nHDon) is a measure of the hydrogen-bonding 
ability of a molecule expressed in terms of 
number of possible hydrogen-bond donors. It is 
calculated by adding up the hydrogens bonded to 
any nitrogen and oxygen without negative charge 
in the molecule.  
Weighted topological atom pairs T(X..Y), 
such as T(N..N), are sums of topological distances 
between all pairs of type X..Y, where X and Y 
referring to any heteroatom among N, O, S, P, F, 
Cl, Br, I.  
The hydrophilic factor (Hy) is a 
hydrophilicity descriptor defined by Todeschini et 
al (42).  
The hydrophilicity (Hy) and H-indices (H7m) 
are selected by both QSPR (logPS) and QSPR 
(logPS-brain) study as significant molecular 
determinant of the rate of brain penetration and 
brain/plasma equilibration rate of the examined 
compounds.  
Predictive potential of the QSPR (logPS-
brain) model was tested by use of leave-one-out 
cross validation of the training set (LOO-CV/Q2: 
0.923, L2O-CV/Q2: 0.918, L3O-CV/Q2: 0.926, 
RMSEE: 0.122) and evaluation of verification set 
(R2Observed vs. Predicted: 0.586, RMSEP: 0.277, and 
R2pred: 0.560) (Table 3). The obtained statistical 
parameters indicated that the QSPR (logPS-brain) 
model could be used as reliable tool for 
evaluation of brain/plasma equilibration rate 
(logPS-brain) of the examined compounds.  
The QSPR (logBB) model with one 
significant components (A=1), relating four 
variables (nHet, SM1_Dz(i), AVS_B(s), and 
TPSA(NO)), R2: 0.714, LOO-CV/Q2: 0.653, L2O-
CV/Q2: 0.652, L3O-CV/Q2: 0.651, F-ratio: 
17.840, P-value: 4.35E-05, and RMSEE: 0.340 
(Table 4), was derived.  
Significant descriptors of the QSPR (logBB) 
model are: nHet - number of 
heteroatoms/Constitutional indices-Basic 
descriptors; SM1_Dz(i) - spectral moment of 
order 1 from Barysz matrix weighted by 
ionization potential/2D matrix-based descriptors-
Barysz matrix weighted by ionization potential 
(Dz(i)); AVS_B(s) - average vertex sum from 
Burden matrix weighted by I-State/2D matrix-
based descriptors-Burden matrix weighted by I-
state (B(s)), and TPSA(NO) - topological polar 
surface area using N,O polar 
contributions/Molecular properties-Basic 
descriptors.  
Since all PLS coefficients of the QSPR 
(logBB) model are negative numbers (Figure 3c, 
Table 4) was concluded that all significant 
descriptors (nHet, SM1_Dz(i), AVS_B(s), and 
TPSA(NO)) are in negative correlation with 
extent of BBB permeation  (logBB). Actually, 
increase in number of heteroatoms (nHet), 
spectral moment of order 1 from Barysz matrix 
weighted by ionization potential (SM1_Dz(i)), 
average vertex sum from Burden matrix weighted 
by I-State (AVS_B(s)), and topological polar 
surface area (TPSA(NO)) of a ligand will lead to 
decrease of logBB. Also, decrease in number of 
heteroatoms (nHet), spectral moment of order 1 
from Barysz matrix weighted by ionization 
potential (SM1_Dz(i)), average vertex sum from 
Burden matrix weighted by I-State (AVS_B(s)), 
and topological polar surface area (TPSA(NO)) of 
a ligand will lead to increase of extent of BBB 
permeation  (logBB). 
The number of heteroatoms (nHet) counts all 
the atoms that are neither hydrogen nor carbon.  
Barysz matrices (Dz(w)) are weighted 
distance matrices accounting contemporarily for 
the presence of heteroatoms and multiple bonds in 
the molecule. They were defined on the basis of a 
generalization of Barysz weighting scheme in 
terms of conventional bond orders π* and any 
atomic property, such as spectral moment of order 
1 from Barysz matrix weighted by ionization 
potential (SM1_Dz(i)) (44). 
Burden matrices (B(w)) are augmented 
adjacency matrices derived from a H-depleted 
molecular graph as the following: the diagonal 
elements are atomic carbon-scaled properties 
(wi/wC); the off-diagonal elements corresponding 
to pairs of bonded atoms are the square roots of 
conventional bond orders; entries corresponding 
to terminal bonds are augmented by 0.1; all other 
matrix elements are set at 0.001. The AVS_B(s) - 
average vertex sum from Burden matrix is 
calculated on the basis of the I-State weighting 
scheme. 
The TPSA(NO) is topological polar surface 
area derived only from polar fragments with 
nitrogen and oxygen (43). The topological polar 
surface area (TPSA(NO)) is parameter selected by 
both QSPR (logPS) and QSPR (logBB) study as 
significant molecular determinant of the rate of 
brain penetration and extent of BBB permeation  
of the examined compounds.  
Predictive potential of the QSPR (logBB) 
model was tested by use of leave-one-out cross 
validation of the training set (LOO-CV/Q2: 0.653, 
L2O-CV/Q2: 0.652, L3O-CV/Q2: 0.651, RMSEE:  
 
 




Table 4. Statistical parameters and predicted extent of BBB permeation obtained by QSPR (logBB) study. 
SD - Standard Deviation, SE – Standard Error: NSDSE / . 
Training Set Extent of BBB permeation  
Primary ID Name logBB (27) QSPR-predicted logBB 
1 Amiloride -2.00 -1.380 
2 Brimonidine -0.21 -0.327 
3 Carvedilol -0.40 -0.377 
4 Clonidine -0.46 -0.097 
5 Clopamide 0.03 -0.731 
6 Clozapine -0.45 -0.056 
7 Doxazosin -1.20 -0.984 
8 Efaroxan 0.40 0.243 
9 Ephedrine -0.02 0.366 
10 Guanfacine -0.24 -0.601 
11 Harmane -0.22 0.235 
12 Harmine -0.05 0.079 
15 Maprotiline 0.97 0.651 
16 Mianserine 0.47 0.494 
18 Naphazoline 0.17 0.369 
19 Olanzapine 0.18 0.061 
20 Oxymetazoline 0.86 0.214 
21 Phenilephrine -0.06 0.016 
24 Tamsulosin -0.35 -0.647 
25 Tetrahydrozoline 0.46 0.464 
27 Triamterene -0.73 -0.903 
28 Tramazoline 0.21 0.273 
F-Ratio 17.840 R2 0.714 
P-value 4.35E-05 LOO-Q2 0.653 
   RMSEE 0.340 
PLS equation:  
Descriptor PLS coefficient SE (PLS coefficient) PLS - Intercept 
nHet -0.219484 0.067757 -0.184448 
SM1-Dz(i) -0.233968 0.068265  
AVS_B(s) -0.220943 0.119724  
TPSA(NO) -0.226892 0.101973  
Test Set 
Primary ID Name logBB (27) QSPR-predicted logBB 
13 Idazoxan -0.10 0.021 
14 Indapamid -0.39 -0.797 
17 Moxonidine -0.26 -0.476 
22 Pseudoephedrine -0.02 0.366 
23 Rilmenidine 0.45 0.357 
26 Tizanidine -0.45 -0.422 
29 Xylometazoline 0.98 0.504 
SD (predicted logBB) = 0.545069 R2Obs vs. Pred 0.678 
   R2pred 0.615 
    RMSEP 0.296 
 
 
0.340) and evaluation of verification set (R2Observed 
vs. Predicted: 0.678, RMSEP: 0.296, and R2pred: 0.615) 
(Table 4). The statistical parameters indicated that 
the created QSPR (logBB) model has acceptable 
accuracy for predicting extent of BBB permeation 
(logBB) of the α-adrenergic and imidazoline 
receptor ligands. In order to investigate the 
statistical significance of the R2 and Q2 and to test 
the model for overfitting due to the chance 
correlation, the response permutation test (Y 




scrambling) is applied for all three created QSPR 
models. The R2–intercepts were less than 0.4 
while the Q2-intercepts were less than 0.05 for the 
three developed QSPR models. Obtained results 
of the response permutation tests have proved that 
the formed QSPR models are not overfitted. 
 
Correlation Study of Pharmacokinetic 
parameters 
The HPLC retention parameters (logKw and 
Slope: logKwpH 4.4, SpH 4.4, logKwpH 7.4, SpH 7.4, 
logKwpH 9.1, and SpH 9.1) and CE migration 
parameters (μeffpH 4.4, μeffpH 7.4, and μeffpH 9.1) of the 
examined 29 ligands were used independent X-
variables, while brain penetration (logPS), 
brain/plasma equilibration rate (logPS-brain), and 
extent of BBB permeation (logBB) were 
dependent - Y variables in the correlation study.  
Because of diverse structures of the 29 α-
adrenergic and imidazoline-receptors ligands, the 
obtained correlations between the 
retention/migration parameters (logKwpH 4.4, SpH 
4.4, logKwpH 7.4, SpH 7.4, logKwpH 9.1, SpH 9.1, μeffpH 
4.0, μeffpH 7.4, and μeffpH 9.1) and the pharmacokinetic 
properties (logPS, logPS-brain, and logBB) were 
very low. Therefore we decided to perform PCA 
and HCA clustering of the ligands before the 
correlation study. 
Molecular descriptors of the examined 
ligands with the strongest influence on the HPLC 
retention parameters (logKwpH 4.4, logKwpH 7.4, 
logKwpH 9.1) and CE migration parameters (μeffpH 
4.4, μeffpH 7.4, and μeffpH 9.1) were also selected for the 
PCA and HCA. The HPLC retention parameters 
(logKwpH 4.4 logKwpH 7.4, logKwpH 9.1), CE 
migration parameters (μeffpH 4.4, μeffpH 7.4, and μeffpH 
9.1), and the selected molecular descriptors were 
used for the PCA and HCA study of the 
compounds (Table 5). 
A percent of modeled variance was used in 
determination of the number of significant 
components (PCs) of the standardized data set 
organized in a matrix X (29 x 34). The PCA 
model with six significant principal components 
(PCs) described 92.31% of the total data variance.  
The PC1 described 57.86% of the total data 
variance. The studied compounds could be 
ordered along the PC1 as follows:  
 
group I: carvedilol and  doxazosin (objects nos 3 
ad 7),  
group II: clopamide, clozapine, indapamid, 
maprotiline, mianserin, olanzapine and tamsulosin 
(compounds No 5, 6,14-16, 19 and 24)  
group III: harmine, oxymetazoline, triamterene 
and xylometazoline (compounds No 12, 20, 27 
and 29),  
group IV: amiloride, brimonidine, clonidine, 
efaroxan, guanfacine, harmane, idazoxan, 
moxonidine, naphazoline, tetrahydrozoline, 
tizanidine and tramazoline (compounds No 1, 2, 
4, 8, 10, 11, 13, 17, 18, 25, 26 and 28) and  
group V: ephedrine, phenilephrine, 
pseudoephedrine and rilmenidine  (compounds 
No 9 and 21-23), respectively.  
 
An efficient compression of the studied data 
was not possible with the PCA and obtained 
results required investigation of many two-
dimensional plots. Therefore, hierarchical 
clustering analysis (HCA) was used to explore the 
studied data set X (29 x 34) and to examine the 
similarities between the studied compounds. HCA 
helped to reveal the internal data structure and its 
clustering tendency. 
The HCA results presented in Figure 4 were 
based on the Euclidean distance and the Ward 
linkage algorithm. 
The dendrogram presented in Figure 4 allows 
revealing four clusters: cluster A grouping 
clozapine, maprotiline, mianserin, olanzapine, 
oxymetazoline and xylometazoline (compounds 
No 6, 15, 16, 19, 20 and 29), cluster B, composed 
of carvedilol, clopamide, doxazosin, indapamid 
and tamsulosin (compounds No 3, 5, 7, 14 and 
24), cluster C grouping amiloride, brimonidine, 
clonidine, guanfacine, harmane, harmine, 
moxonidine, tizanidine and triamterene 
(compounds No 1, 2, 4, 10-12, 17, 26 and 27) and 
cluster D including efaroxan, ephedrine, 
idazoxan, naphazoline, phenilephrine, 
pseudoephedrine, rilmenidine, tetrahydrozoline 
and tramazoline (compounds No 8, 9, 13, 18, 21-
23, 25 and 28). 
Because of very high similarity between I-II 
and III-IV PCA groups with A-B and C-D HCA 
clusters, respectively, we further examined HCA-
groups A and B, as first subset, and HCA-groups 
C and D, as second subset, in correlation study 
with rate of brain penetration (logPS), extent of 
BBB permeation  (logBB), and brain/plasma 
equilibration rate (logPS-brain) of the 
compounds.  
Significant correlations were obtained 
between the chromatographic retention parameter 
(S at pH 7.4) and extent of BBB permeation 
(logBB) in A/B cluster (r(SpH7.4/logBB): 0.677) 
(Figure 5a), and also between the 
chromatographic retention parameter (logKw at 
pH 9.1) and rate of brain penetration (logPS) in 
C/D cluster (r(logKwpH 9.1/logPS): 0.684) (Figure 
5b).  





Table 5. Descriptors used for PCA and HCA study. 
No. Descriptor No. Descriptor No. Descriptor 
1 logKw pH 4.4 12 VE2_Dt 24 GGI6 
2 logKw pH 7.4 13 H_D/Dt 25 G1 
3 logKw pH 9.1 14 Ho_Dt 26 RDF045e 
4 μeff pH 4.4 15 SM3_Dt 27 Mor32m 
5 μeff pH 7.4 16 LogD 7,4 28 SpMaxA_EA(dm) 
6 μeff pH 9.1 17 F04[C-C] 29 SM1_Dz(Z) 
7 SM04_EA(ri) 18 logD 9,1 30 AAC 
8 SpMax5_Bh(i) 19 ALOGP 31 ZM1MulPer 
9 SM02_EA(ri) 20 ATS6s 32 SM11_EA(dm) 
10 VE2_Dz(p) 21 Ho_Dz(e) 33 ISH 
11 SpMax5_Bh(e) 22 ATS7s 34 MW 
  23 ATSC6m   
 
 
Figure 4. The dendrograms of studied compounds (objects) in the space of the 34 descriptors (listed in Table 5). 
 
 
Positive sign of correlation coefficient between 
slope SpH7.4 and logBB (r(SpH7.4/logBB): 0.677) in 
A/B cluster indicate that ligands with lower SpH7.4 
values will have lower logBB values and 
therefore decreased extent of BBB permeation, 
while ligands with higher SpH7.4 values will have 
higher logBB values and therefore increased 
extent of BBB permeation. 




Positive sign of correlation coefficient 
between logKwpH9.1 and logPS 
(r(logKwpH9.1/logPS): 0.684) in C/D cluster 
indicate that ligands with lower logKwpH9.1 values 
will have lower logPS values and therefore 
decreased rate of brain penetration, while ligands 
with higher logKwpH9.1 values will have higher 
logPS values and therefore increased rate of brain 
penetration. 
Generally, the compounds in A/B cluster 
have: MW > 260, logKwpH4.0 > 2, logKwpH7.4 > 2, 
and logKwpH9.1 > 2, while the ligands grouped in 
C/D cluster have: MW<260, logKwpH4.0 < 2, 
logKwpH7.4 < 2, and logKwpH9.1 < 2. 
Therefore, in case of related α-
adrenergic/imidazoline receptor ligands with MW 
> 260, logKwpH4.0 > 2, logKwpH7.4 > 2, and 
logKwpH9.1 > 2 parameters, the derived linear 
equation (logBB = 0.6874*S7.4+3.05) could be 
applied for evaluation of their extent of BBB 
permeation. Also, in case of ligands with MW < 
260, logKwpH4.0 < 2, logKwpH7.4 < 2, and 
logKwpH9.1 < 2 parameters, the derived linear 
equation (logPS = 1.006*logKw9.1-4.229) could 
be applied for evaluation of their rate of brain 
penetration.  
Results of the clustering and correlation 
studies could be readily used as time and cost 
efficient screening method for evaluation of brain 
penetration process of novel α-





Rate of brain penetration (logPS), brain/plasma 
equilibration rate (logPS-brain), and extent of 
BBB permeation (logBB) were examined by 
QSPR study for 29 α-adrenergic and imidazoline-
receptors ligands. Experimental parameters 
((logKwpH 4.4, SpH 4.4, logKwpH 7.4, SpH 7.4, logKwpH 
9.1, SpH 9.1, μeffpH 4.4, μeffpH 7.4, and μeffpH 9.1) and 
calculated molecular descriptors of the ligands 
were used as independent variables in the QSPR 
study.  
The QSPR (logPS) study indicated on 
negative correlation between hydrophilicity (Hy), 
topological polar surface area (TPSA(NO)), mean 
first ionization potential (Mi), H7m indices, and 
R3s+ indices of the α-AR/IR ligands and rate of 
brain penetration (logPS). Therefore increase in 
Hy, TPSA(NO), Mi, H7m, and R3s+ values of a 
ligand will lead to decrease of rate of brain 
penetration (logPS), and vice versa.  
The QSPR (logPS-brain) study signified 
negative correlation between GATS1e parameter, 
H7m indices, nHDon, T(N..N) and hydrophilicity 
(Hy) of the α-AR/IR ligands and brain/plasma 
equilibration rate (logPS-brain).  Thus increase in 
GATS1e, H7m, nHDon, T(N..N) and Hy, values 
of a ligand will lead to decrease of brain/plasma 
equilibration rate (logPS-brain), and opposite.  
The hydrophilicity (Hy) and H7m indices are 
selected by both QSPR (logPS) and QSPR 
(logPS-brain) studies as significant molecular 
determinant of the compounds for rate of brain 
penetration and brain/plasma equilibration rate.  
The QSPR (logBB) study indicated on 
negative correlation between nHet, SM1_Dz(i), 
AVS_B(s), and TPSA(NO) of the α-AR/IR 
ligands and extent of BBB permeation (logBB). 
Therefore increase in nHet, SM1_Dz(i), 
AVS_B(s), and TPSA(NO) values of a ligand will 
lead to decrease of extent of BBB permeation 
(logBB), and vice versa.  
The topological polar surface area 
(TPSA(NO)) is parameter chosen by both QSPR 
(logPS) and QSPR (logBB) studies as significant 
molecular determinant of the rate of brain 
penetration and extent of BBB permeation of the 
examined compounds.  
The hydrophilicity (Hy) and topological polar 
surface area (TPSA(NO)) are common significant 
descriptors of QSPR (logPS)/QSPR (logPS-brain) 
and QSPR (logPS)/QSPR (logBB) models 
respectively. The observed negative correlations 
of the hydrophilicity and topological polar surface 
area on blood-brain penetrations process were in 
very good agreement with previously reported 
QSPR studies of brain penetration of other groups 
of organic compounds (45).  
Prognostic capacity of the created QSPR 
(logPS, logPS-brain, logBB) models was proved 
by cross- and external validation.  
Therefore structures of novel test compounds 
could be examined by the presented QSPR 
procedure that includes: molecular modeling, 
calculation of molecular parameters of the 
optimized molecular models, and prediction of the 
logPS, logPS-brain, logBB values by use of the 
formed QSPR (logPS, logPS-brain, logBB) 
models. 
After PCA and HCA grouping were obtained 
good correlations between the chromatographic 
retention parameter (SpH7.4) and logBB in A/B 
cluster, and between the chromatographic 
retention parameter (logKwpH9.1) and logPS in 
C/D cluster. 
Structural diversity of the examined drugs 
provide wide application domain of the QSPR 
models, which could be used for evaluation of 
brain penetration of related α-
adrenergic/imidazoline receptor ligands. 
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Supplement Table 1. Values of the significant descriptors used in the QSPR (logPS) model. 
 
Primary ID Training Set Mi H7m R3s+ Hy TPSA(NO) 
1 Amiloride 1.176 0.201 0.728 6.789 156.79 
2 Brimonidine 1.135 0.036 0.339 1.309 63.81 
3 Carvedilol 1.123 0.079 0.141 1.564 80.32 
5 Clopamide 1.136 0.009 0.268 1.159 92.50 
6 Clozapine 1.127 0.097 0.169 0.278 36.36 
7 Doxazosin 1.133 0.064 0.247 0.252 112.27 
8 Efaroxan 1.129 0.007 0.129 -0.291 33.62 
9 Ephedrine 1.136 0.003 0.284 1.394 36.84 
10 Guanfacine 1.136 0.000 0.289 2.350 78.97 
11 Harmane 1.111 0.000 0.193 -0.305 28.68 
12 Harmine 1.117 0.001 0.138 -0.291 37.91 
13 Idazoxan 1.129 0.006 0.201 -0.200 42.85 
15 Maprotiline 1.117 0.008 0.053 0.143 16.61 
17 Moxonidine 1.156 0.024 0.260 1.433 73.04 
18 Naphazoline 1.119 0.001 0.074 0.329 26.00 
19 Olanzapine 1.127 0.031 0.070 0.304 36.36 
22 Pseudoephedrine 1.136 0.002 0.260 1.394 36.84 
23 Rilmenidine 1.142 0.007 0.125 -0.202 33.62 
24 Tamsulosin 1.133 0.142 0.222 1.698 104.46 
26 Tizanidine 1.136 0.104 0.232 1.433 63.81 
28 Tramazoline 1.136 0.005 0.072 1.189 38.03 
29 Xylometazoline 1.134 0.013 0.046 0.265 26.00 
Primary ID Test Set Mi H7m R3s+ Hy TPSA(NO) 
4 Clonidine 1.135 0.035 0.313 1.453 38.03 
14 Indapamid 1.122 0.015 0.293 1.080 92.50 
16 Mianserine 1.118 0.014 0.061 -0.886 6.48 
20 Oxymetazoline 1.136 0.011 0.188 1.044 46.23 
21 Phenilephrine 1.139 0.002 0.332 2.456 57.07 
25 Tetrahydrozoline 1.128 0.004 0.071 0.366 26.00 
27 Triamterene 1.144 0.012 0.130 3.956 129.62 
 




Supplement Table 2. Values of the significant descriptors used in the QSPR (logPS-brain) model. 
 
Primary ID Training Set GATS1e H7m nHDon T(N..N) Hy 
1 Amiloride 1.232 0.201 8 80 6.789 
2 Brimonidine 1.075 0.036 3 38 1.309 
3 Carvedilol 0.998 0.079 4 8 1.564 
5 Clopamide 0.531 0.009 3 13 1.159 
6 Clozapine 0.922 0.097 2 22 0.278 
7 Doxazosin 0.891 0.064 2 28 0.252 
8 Efaroxan 0.901 0.007 1 0 -0.291 
9 Ephedrine 1.196 0.003 3 0 1.394 
10 Guanfacine 0.816 0.000 4 0 2.350 
11 Harmane 0.971 0.000 1 3 -0.305 
12 Harmine 0.909 0.001 1 3 -0.291 
13 Idazoxan 0.910 0.006 1 0 -0.200 
15 Maprotiline 1.389 0.008 2 0 0.143 
17 Moxonidine 0.997 0.024 3 26 1.433 
18 Naphazoline 1.192 0.001 2 0 0.329 
19 Olanzapine 1.125 0.031 2 22 0.304 
22 Pseudoephedrine 1.196 0.002 3 0 1.394 
23 Rilmenidine 0.894 0.007 1 0 -0.202 
24 Tamsulosin 0.776 0.142 4 7 1.698 
26 Tizanidine 0.916 0.104 3 29 1.433 
28 Tramazoline 1.241 0.005 3 0 1.189 
29 Xylometazoline 1.241 0.013 2 0 0.265 
Primary ID Test Set GATS1e H7m nHDon T(N..N) Hy 
4 Clonidine 0.869 0.035 3 0 1.453 
14 Indapamid 0.528 0.015 3 13 1.080 
16 Mianserine 0.992 0.014 0 3 -0.886 
20 Oxymetazoline 1.105 0.011 3 0 1.044 
21 Phenilephrine 1.158 0.002 4 0 2.456 
25 Tetrahydrozoline 1.195 0.004 2 0 0.366 
27 Triamterene 1.268 0.012 6 62 3.956 
 




Supplement Table 3. Values of the significant descriptors used in the QSPR (logBB) model. 
 
Primary ID Training Set nHet SM1_Dz(i) AVS_B(s) TPSA(NO) 
1 Amiloride 9 1.058 5.490 156.79 
2 Brimonidine 6 0.776 4.694 63.81 
3 Carvedilol 6 0.762 4.688 80.32 
4 Clonidine 5 0.662 4.676 38.03 
5 Clopamide 8 0.806 5.062 92.50 
6 Clozapine 5 0.709 4.537 36.36 
7 Doxazosin 10 1.096 4.821 112.27 
8 Efaroxan 3 0.485 4.449 33.62 
9 Ephedrine 2 0.335 4.478 36.84 
10 Guanfacine 6 0.748 5.206 78.97 
11 Harmane 2 0.372 4.780 28.68 
12 Harmine 3 0.485 4.772 37.91 
15 Maprotiline 1 0.203 4.320 16.61 
16 Mianserine 2 0.372 4.396 6.48 
18 Naphazoline 2 0.372 4.509 26.00 
19 Olanzapine 5 0.595 4.436 36.36 
20 Oxymetazoline 3 0.485 4.409 46.23 
21 Phenilephrine 3 0.452 4.798 57.07 
24 Tamsulosin 8 0.802 4.787 104.46 
25 Tetrahydrozoline 2 0.372 4.302 26.00 
27 Triamterene 7 0.946 5.064 129.62 
28 Tramazoline 3 0.516 4.306 38.03 
Primary ID Test Set nHet SM1_Dz(i) AVS_B(s) TPSA(NO) 
13 Idazoxan 4 0.586 4.602 42.85 
14 Indapamid 8 0.806 5.206 92.50 
17 Moxonidine 7 0.888 4.673 73.04 
22 Pseudoephedrine 2 0.335 4.478 36.84 
23 Rilmenidine 3 0.485 4.202 33.62 
26 Tizanidine 7 0.775 4.782 63.81 






















Figure 3. Coefficient Plots: a) QSPR(logPS) model. 






Figure 3. Coefficient Plots: b) QSPR(logPS-brain) model. 
 





Figure 3. Coefficient Plots: c) QSPR(logBB) model. 





Figure 5. Linear correlation plots: a) HPLC retention parameter - Slope at 7.4 vs. extent of BBB permeation (logBB) in A/B cluster.






Figure 5. Linear correlation plots: b) HPLC retention parameter - logKw at 9.1 vs. rate of brain penetration (logPS) in C/D cluster. 
 
 
